Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.32 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489866 | 1.00 | LIPG (0.48) | LIPGENPP2ALDH1A1HPGDLIPE | |
| SCHEMBL29809738 | 0.77 | ALDH1A1 (0.56) | ENPP2ALDH1A1HPGDFFAR1FFAR4 | |
| SCHEMBL1945874 | 0.77 | ALDH1A1 (0.56) | ENPP2ALDH1A1HPGDFFAR1FFAR4 | |
| SCHEMBL3229542 | 0.76 | ALDH1A1 (0.33) | LIPGALDH1A1HPGD | |
| Water SCHEMBL3179940 | 0.76 | LIPG (0.53) | LIPGENPP2LIPEORAI1ORAI2 | |
| SCHEMBL20519418 | 0.73 | GPBAR1 (0.36) | ENPP2KMT2ACYP2A6 | |
| SCHEMBL29468961 | 0.73 | LIPG (0.61) | LIPGENPP2ALDH1A1LIPE | |
| SCHEMBL8530 | 0.73 | LIPG (0.55) | LIPGENPP2LIPEORAI1ORAI2 | |
| SCHEMBL410387 | 0.73 | LIPG (0.61) | LIPGENPP2ALDH1A1LIPE | |
| SCHEMBL29377890 | 0.73 | LIPG (0.55) | LIPGENPP2LIPEORAI1ORAI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4137489-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-109890819-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | disclosed |
| EP-3472167-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114008048-A | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210317139-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-10-14 | — | — | US | disclosed |
| WO-2020257429-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3472167-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2009029439-A1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1891019-A2 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2006044732-A2 | 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050118209-A1 | Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-02 | — | — | US | disclosed |
| US-20040235792-A1 | Serine protease inhibitors compromising a hydrogen-bond acceptor | TRIGEN LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
| WO-2002057273-A9 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LTD (GB) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002057273-A1 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | LIPG 777/4885ENPP2 17/4885ALDH1A1 527/4885 |
| US-20210317139-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | LIPG 1666/4885ENPP2 191/4885ALDH1A1 223/4885 |
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | LIPG 1666/4885ENPP2 191/4885ALDH1A1 223/4885 |
| US-20040235792-A1 | Serine protease inhibitors compromising a hydrogen-bond acceptor | SERPINB1, SPINT2, CTRL | LIPG 1799/4885ENPP2 1293/4885ALDH1A1 3567/4885 |
| US-20050118209-A1 | Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides | CAT, LPO, GPX4 | LIPG 916/4885ENPP2 2806/4885ALDH1A1 184/4885 |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | LIPG 1765/4885ENPP2 90/4885ALDH1A1 639/4885 |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | LIPG 1765/4885ENPP2 90/4885ALDH1A1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.